Dravet syndrome
ICD-10 G40.8 · ICD-11 8A61.11

First-Line Antiseizure Treatment for Dravet Syndrome

Dravet syndrome is a severe developmental and epileptic encephalopathy that requires prompt, well-chosen antiseizure pharmacotherapy from the outset. Selecting the right first-line agent is critical to reducing the most dangerous seizure events early in the course.

Clinical Goals

The central aim is to prevent prolonged convulsive seizures and status epilepticus. When the most serious events are controlled, infrequent and brief convulsive seizures may be an acceptable outcome.

Treatment Approach

Management is built around antiseizure pharmacotherapy. The first-line approach involves a specific established antiseizure medication, with an alternative agent available as an early option in selected cases.

The complete regimen — including sequencing, full agent selection, and clinical decision points — is in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens
References
DOI: 10.1111/epi.17274

Valproic acid is an appropriate first-line drug, and clobazam can be considered as either the initial or second antiseizure medication (ASM; Strong).

There was consensus for use of valproic acid as first-line therapy, and for use of clobazam, fenfluramine, or stiripentol as first-or second-line therapy.

In DS, it is appropriate to accept infrequent, brief convulsive seizures with the main goal focused on avoiding prolonged convulsive seizures and status epilepticus (physicians: n = 19, 79%; caregivers: n = 9, 56%).

View source ↗